Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126534 | 1.00 | HCAR2 (0.48) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL425749 | 0.96 | HCAR2 (0.48) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL425748 | 0.96 | HCAR2 (0.48) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL9744705 | 0.94 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL14363086 | 0.94 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL1581948 | 0.94 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL1581950 | 0.94 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL9744701 | 0.94 | HCAR2 (0.47) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL7512241 | 0.92 | HCAR2 (0.52) | HCAR2L3MBTL1MAPTTDP1CA12 | |
| SCHEMBL7512242 | 0.92 | HCAR2 (0.52) | HCAR2L3MBTL1MAPTTDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20180155342-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2018-06-07 | — | — | US | disclosed |
| US-9908878-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2739623-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| US-9394302-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394302-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-4551476-A | 13,14-Didehydro-prostaglandins and process for their preparation | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-11-05 | — | — | US | disclosed |
| US-4361577-A | ANTIULCER AND LUTEOLYTIC AGENTS | CARLO ERBA - S.P.A. (IT) | 1982-11-30 | — | — | US | disclosed |
| US-4169145-A | ANTIULCER AGENTS, LUTEOLYTIC ABORTIFACIENTS, OXYTOCICS | CARLO ERBA S.P.A. (IT) | 1979-09-25 | — | — | US | disclosed |
| US-4035415-A | GASTROINTESTINAL DISORDERS | CARLO ERBA, S.P.A. (IT) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | HCAR2 67/4885L3MBTL1 4560/4885MAPT 4550/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HCAR2 1027/4885L3MBTL1 2898/4885MAPT 2938/4885 |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | HCAR2 2767/4885L3MBTL1 1045/4885MAPT 1696/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | HCAR2 2767/4885L3MBTL1 1045/4885MAPT 1696/4885 |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | HCAR2 4318/4885L3MBTL1 4589/4885MAPT 3241/4885 |
| US-20180155342-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | HCAR2 4318/4885L3MBTL1 4589/4885MAPT 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.